The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board ...
A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.